Intrathecal drug delivery systems may be ineffective in reducing pain and oral opioid intake in individuals with complex regional pain syndrome, according to a study recently published in Pain Medicine.
This study included 1653 individuals with implanted intrathecal drug delivery systems, 62 of whom had received the device to alleviate complex regional pain syndrome-related pain(n=26 with ≥ 4 years of follow-up data). Participants in this study received an intrathecal drug delivery system implant between 2000 and 2013. The primary outcomes for this study included pain intensity and oral intake of opioids.
“[I]ntrathecal opioid dose was not associated with long-term decreases in oral opioid intake. Additionally, ziconotide was associated with a decrease in oral opioid intake over the four-year follow-up, and bupivacaine was associated with an increase in oral opioid intake…. Our findings suggest that intrathecal opiates may not be effective in reducing oral opiate intake; ziconotide may hasten a decrease in intake; and bupivacaine may lead to an increase in intake,” concluded the study authors.
Herring EZ, Frizon LA, Hogue O, et al. Long-term outcomes using intrathecal drug delivery systems in complex regional pain syndrome Pain Med.